SEC Form 4 · accession 0001209191-17-037514
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jose E Rivera
Officer — EVP, General Counsel & Ops
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 7:57 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 1, 2017 | A | 8,400 | $12.0327 | A | 8,994 | D | |
| Common StockF3 | holding | — | — | — | 262,210 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 to $12.04, inclusive.
- F2Includes 594 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2016.
- F3Shares are held by Rivak Capital LLC, or Rivak. Mr. Rivera is a member and manager of Rivak and has voting and dispositive power over the shares.